Show simple item record

dc.contributor.authorGuimarães, Douglas M.pt_BR
dc.contributor.authorAlmeida, Luciana Oliveirapt_BR
dc.contributor.authorMartins, Manoela Dominguespt_BR
dc.contributor.authorWarner, Kristypt_BR
dc.contributor.authorSantos-Silva, Alan Rogerpt_BR
dc.contributor.authorVargas, Pablo Agustinpt_BR
dc.contributor.authorNunes, Fábio Daumaspt_BR
dc.contributor.authorSquarize, Cristiane Helenapt_BR
dc.contributor.authorNor, Jacques Eduardopt_BR
dc.contributor.authorCastilho, Rogerio Moraespt_BR
dc.date.accessioned2018-10-26T02:43:25Zpt_BR
dc.date.issued2016pt_BR
dc.identifier.issn1949-2553pt_BR
dc.identifier.urihttp://hdl.handle.net/10183/183990pt_BR
dc.description.abstractMucoepidermoid carcinoma (MEC) is the most common malignancy of salivary glands. The response of MEC to chemotherapy is unpredictable, and recent advances in cancer biology suggest the involvement of cancer stem cells (CSCs) in tumor progression and chemoresistance and radioresistance phenotype. We found that histone acetyltransferase inhibitors (HDACi) were capable of disrupting CSCs in MEC. Furthermore, administration of HDACi prior to Cisplatin (two-hit approach) disrupts CSCs and sensitizes tumor cells to Cisplatin. Our findings corroborate to emerging evidence that CSCs play a key role in tumor resistance to chemotherapy, and highlights a pharmacological two-hit approach that disrupts tumor resistance to conventional therapy.en
dc.format.mimetypeapplication/pdfpt_BR
dc.language.isoengpt_BR
dc.relation.ispartofOncotarget. Albany. Vol. 7, no. 27 (July 2016), p. 42447-42460pt_BR
dc.rightsOpen Accessen
dc.subjectPatologia bucalpt_BR
dc.subjectCarcinoma bucalpt_BR
dc.subjectCélulas-tronco neoplásicaspt_BR
dc.titleSensitizing mucoepidermoid carcinomas to chemotherapy by targeted disruption of cancer stem cellspt_BR
dc.typeArtigo de periódicopt_BR
dc.identifier.nrb001059508pt_BR
dc.type.originEstrangeiropt_BR


Files in this item

Thumbnail
   

This item is licensed under a Creative Commons License

Show simple item record